145 related articles for article (PubMed ID: 30212182)
41. Pharmacological properties of R-84760, a novel kappa-opioid receptor agonist.
Fujibayashi K; Sakamoto K; Watanabe M; Iizuka Y
Eur J Pharmacol; 1994 Aug; 261(1-2):133-40. PubMed ID: 8001635
[TBL] [Abstract][Full Text] [Related]
42. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
43. Association of in vivo κ-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology.
Pietrzak RH; Naganawa M; Huang Y; Corsi-Travali S; Zheng MQ; Stein MB; Henry S; Lim K; Ropchan J; Lin SF; Carson RE; Neumeister A
JAMA Psychiatry; 2014 Nov; 71(11):1262-1271. PubMed ID: 25229257
[TBL] [Abstract][Full Text] [Related]
44. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
45. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
[TBL] [Abstract][Full Text] [Related]
46. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
Hjorth SA; Thirstrup K; Schwartz TW
Mol Pharmacol; 1996 Oct; 50(4):977-84. PubMed ID: 8863844
[TBL] [Abstract][Full Text] [Related]
47. kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception.
Butelman ER; Ko MC; Sobczyk-Kojiro K; Mosberg HI; Van Bemmel B; Zernig G; Woods JH
J Pharmacol Exp Ther; 1998 May; 285(2):595-601. PubMed ID: 9580603
[TBL] [Abstract][Full Text] [Related]
48. [11C]-MeJDTic: a novel radioligand for kappa-opioid receptor positron emission tomography imaging.
Poisnel G; Oueslati F; Dhilly M; Delamare J; Perrio C; Debruyne D; Barré L
Nucl Med Biol; 2008 Jul; 35(5):561-9. PubMed ID: 18589300
[TBL] [Abstract][Full Text] [Related]
49. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
50. HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.
Lattanzi R; Negri L; Giannini E; Schmidhammer H; Schutz J; Improta G
Br J Pharmacol; 2001 Sep; 134(2):441-7. PubMed ID: 11564664
[TBL] [Abstract][Full Text] [Related]
51. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor.
Kong H; Raynor K; Yano H; Takeda J; Bell GI; Reisine T
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8042-6. PubMed ID: 8058754
[TBL] [Abstract][Full Text] [Related]
52. Age and sex regulate kappa opioid receptor-mediated anxiety-like behavior in rats.
Przybysz KR; Varlinskaya EI; Diaz MR
Behav Brain Res; 2020 Feb; 379():112379. PubMed ID: 31765725
[TBL] [Abstract][Full Text] [Related]
53. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay.
Romero DV; Partilla JS; Zheng QX; Heyliger SO; Ni Q; Rice KC; Lai J; Rothman RB
Synapse; 1999 Nov; 34(2):83-94. PubMed ID: 10502307
[TBL] [Abstract][Full Text] [Related]
54. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.
Willmore-Fordham CB; Krall DM; McCurdy CR; Kinder DH
Neuropharmacology; 2007 Sep; 53(4):481-6. PubMed ID: 17681558
[TBL] [Abstract][Full Text] [Related]
55. [11C]GR103545: novel one-pot radiosynthesis with high specific activity.
Nabulsi NB; Zheng MQ; Ropchan J; Labaree D; Ding YS; Blumberg L; Huang Y
Nucl Med Biol; 2011 Feb; 38(2):215-21. PubMed ID: 21315277
[TBL] [Abstract][Full Text] [Related]
56. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats.
Jewett DC; Grace MK; Jones RM; Billington CJ; Portoghese PS; Levine AS
Brain Res; 2001 Aug; 909(1-2):75-80. PubMed ID: 11478923
[TBL] [Abstract][Full Text] [Related]
57. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
[TBL] [Abstract][Full Text] [Related]
58. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753.
Barber A; Bartoszyk GD; Bender HM; Gottschlich R; Greiner HE; Harting J; Mauler F; Minck KO; Murray RD; Simon M
Br J Pharmacol; 1994 Dec; 113(4):1317-27. PubMed ID: 7889287
[TBL] [Abstract][Full Text] [Related]
59. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
60. GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity.
Rogers H; Birch PJ; Harrison SM; Palmer E; Manchee GR; Judd DB; Naylor A; Scopes DI; Hayes AG
Br J Pharmacol; 1992 Aug; 106(4):783-9. PubMed ID: 1327387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
